Cingulate Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Industry Veteran Bryan Downey Named Chief Commercial Officer 
NDA Accepted with May 2026 PDUFA Date
Commercial Supply Agreement Executed

KANSAS CITY, Kan., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to build a pipeline of next-generation products, today announced financial results for the quarter ended September 30, 2025, and provided recent corporate highlights.

Read more at globenewswire.com